This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(3 sites)

United States

Dana Farber Cancer Institute, Boston, Massachusetts

NEXT Oncology, Austin, TX 78758, Texas

NEXT Oncology, San Antonio, Texas